Print Page     Close Window     

SEC Filings

20-F
AC IMMUNE SA filed this Form 20-F on 03/21/2019
Entire Document
 

CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 24B-2
UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

 

Capitalized terms not defined above have the meaning set forth in the sections below.
ACI Preamble
ACI Program IP Section ‎8.1.3
ACI Proposed Budget Section ‎3.2.2
ACI Unilateral Clinical Development Proposal” Section 3.2.2
Additional Indication Section ‎7.6.4
Additional Indication Clinical Funding Option Section ‎‎7.6.4
Agreement Preamble
Arbitration Notice Section ‎13.5.1
Arbitrators Section ‎13.5.2
Assigned Regulatory Approvals Section 3.3.1‎(iii)
Assigned Regulatory Documentation Section 3.3.1‎(iii)
Auditor Section ‎‎7.11.1
Board of Directors Section ‎1.13.1
Breaching Party Section ‎12.2.1
Combination Product Section ‎1.76
Competitive Change of Control Section ‎2.7.2
Competitive Change of Control Cure Section 2.7.2
Competitive Change of Control Cure Period Section 2.7.2
Confidential Information Section ‎9.1

 

 15


© AC Immune 2015